1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) September 28, 1999
SONUS PHARMACEUTICALS, INC.
(Exact name of Registrant as specified in its charter)
Delaware 0-26866 95-4343413
---------------------------- ------------ ------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No)
22026 20th Avenue S.E., Bothell, Washington 98021
-------------------------------------------- ---------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (425) 487-9500
Not Applicable
--------------
(Former name or former address, if changed since last report)
Page 1 of 4
Exhibit Index on Page 4
2
ITEMS 1 THROUGH 4, 6, 8 AND 9 ARE NOT APPLICABLE.
ITEM 5. ACQUISITION OR DISPOSITION OF ASSETS
The license agreement between SONUS Pharmaceuticals, Inc. and
Nycomed Imaging AS dated August 31, 1999 became effective on September 28, 1999.
The text of which is attached hereto as Exhibit 10.36.
Reference is made to the press release issued to the public by the
registrant on September 29, 1999, the text of which is attached hereto as
Exhibit 99.1, for a description of the events reported pursuant to this Form
8-K.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS
(a) Financial Statements
Not Applicable
(b) Pro Forma Financial Information
Not Applicable
(c) Exhibits
EXHIBIT NO. DESCRIPTION
----------- -----------
10.36 License Agreement by and between Nycomed Amersham AS
and SONUS Pharmaceuticals, Inc. dated August 31, 1999.
99.1 Press Release dated September 29, 1999.
2
3
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.
SONUS PHARMACEUTICALS, INC.
Date: October 12, 1999 By: /s/ Gregory Sessler
-------------------------------------
Gregory Sessler
Chief Financial Officer
3
4
EXHIBIT INDEX
EXHIBIT NO. DESCRIPTION
- ----------- -----------
10.36 License Agreement by and between Nycomed Amersham AS and
SONUS Pharmaceuticals, Inc. dated August 31, 1999.
99.1 Press Release dated September 29, 1999.
4